Xcout IntelSign inSubscribe

Boehringer Ingelheim

PharmaceuticalsGermany

Boehringer Ingelheim is a privately held pharmaceutical company that develops and manufactures prescription medicines for human healthcare, including therapies in areas such as cardiovascular, respiratory, metabolic, immunology and oncology. It also provides animal-health medicines and vaccines through its Boehringer Ingelheim Animal Health business, serving healthcare professionals, patients and veterinary customers worldwide.

Subscribe to see Boehringer Ingelheim’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Industry
Pharmaceuticals
Headquarters
Germany

Recent Boehringer Ingelheim news

Boehringer Ingelheim competitors

A few of Boehringer Ingelheim's closest competitors — see the full list of competitors and alternatives →

Merck & Company, Inc. Common Stock (new)MRK · PharmaceuticalsRahway, United States
67% matchPublic

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Market cap$359.6B
Employees73,000
Merck & Company, Inc. Common Stock (new) competitors & alternatives →

Get Boehringer Ingelheim's news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Boehringer Ingelheim — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Boehringer Ingelheim in Xcout Intel

  • 2 corporate events with sources — deals, leadership changes, layoffs
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →